CoChat

Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes

Open access
Al-Najim, Werd, Raposo, António, BinMowyna, Mona N., le Roux, Carel W. · 2025 · Nutrients

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index; 17 of the 60 sources its claims cite were checked for support.

Abstract

Background/Objectives: Obesity pharmacotherapy vastly improved the treatment of the disease of obesity. However, GLP-1 receptor agonists and GIP/GLP-1 dual agonists may lead to nutritional complications, including severe caloric restriction, micronutrient deficiencies, lean body mass loss, dehydration, and ketosis. We examine these risks and outlines dietitian-led strategies to support improved safety and effectiveness. Methods: This narrative review was conducted in three stages: literature search, screening of abstracts and full texts, and synthesis of findings. Searches were carried out in April and May 2025 across PubMed, Embase, Scopus, ScienceDirect, Web of Science, and Google Scholar using keywords related to obesity pharmacotherapy and nutrition. Results: Clinical observations and trial data suggest that some individuals may consume fewer than 800 kcal/day during the initial stages of treatment. Prolonged energy and protein deficits can increase the risk of sarcopenia, metabolic dysfunction, and reduce treatment adherence. Additional risks include inadequate micronutrient intake due to reduced dietary variety, dehydration linked to gastrointestinal symptoms and hypodipsia, and rare but serious cases of ketoacidosis. Patients at heightened risk include older adults, those with low baseline muscle mass, and individuals with restrictive eating patterns. Conclusions: Obesity medications introduce unique nutritional risks that are not yet addressed by standardised clinical protocols. Registered dietitians play a critical role in assessing intake patterns, monitoring for red flags, and delivering targeted nutritional support. Integrating structured dietary assessment tools, checklists, and risk-specific guidance into pharmacotherapy pathways can enhance safety, promote adherence, and improve long-term outcomes.

Overview

CoChat Summary

TL;DR

This narrative review argues that GLP-1 receptor agonists and dual GIP/GLP-1 agonists can produce under-recognized nutritional harms—severe caloric restriction, lean mass loss, micronutrient deficiencies, dehydration, and ketosis—that standard pharmacotherapy pathways do not yet address. It proposes dietitian-led monitoring and a practice-oriented checklist, though the checklist has not been validated.

Key findings

  • Some patients may consume fewer than 800 kcal/day during early treatment; gastrointestinal adverse events were reported in up to 74% of trial participants, with approximately 7–10% discontinuing due to intolerable symptoms.
  • Lean mass loss varies by trial: STEP 1 reported semaglutide-associated lean mass reduction of 6.9 kg (−13.2%) out of 15.3 kg (−14.9%) total weight loss, about 45% of weight lost as lean mass; SURMOUNT-1 attributed 25.7% of weight lost with tirzepatide to lean mass; SUSTAIN-8 reported 2.3 kg (−4.5%) lean mass loss out of 5.3 kg (−6.0%) total weight loss, or 43.4%.
  • Micronutrient gaps were common in an exploratory study: average fiber intake was 14.5 g/day versus a recommended 28 g/day, and vitamin D intake was 4 mcg/day; pre-existing deficiency data included 46% vitamin D deficiency in a Chilean severe-obesity cohort and, in a Spanish cohort, 10% vitamin B12, 25% folate, 26% vitamin D, 68% copper, and 74% zinc deficiencies.
  • Dehydration and ketosis risks include semaglutide showing the highest risk of fluid reduction-related adverse events in a pharmacovigilance analysis, and liraglutide being associated with increased odds of ketosis in type 1 diabetes (OR 1.8; 95% CI, 1.1–2.8).

Methods

  • Narrative review conducted in three stages: literature search, screening of abstracts and full texts, and synthesis of findings.
  • Searches were run in April and May 2025 across PubMed, Embase, Scopus, ScienceDirect, Web of Science, and Google Scholar using keywords related to obesity pharmacotherapy and nutrition; only English-language publications were included.
  • Eligible sources included clinical trials, observational studies, case reports, practice guidelines, and narrative reviews; no formal PRISMA flow diagram was used.

Limitations

  • The authors state that the search was not systematic or meta-analytic, no formal quality appraisal or risk-of-bias tools were applied, and inclusion relied on relevance and clinical judgement, which may introduce subjectivity.
  • The authors state that the proposed checklist and targeted strategies were developed from literature and expert practice considerations but have not been validated or empirically tested in clinical settings.
  • Evident from the text: some key evidence is indirect or limited, including micronutrient deficiency data drawn from bariatric surgery populations, limited published data on actual caloric intake, and limited evidence on higher GLP-1RA doses used for obesity.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/nu17111934

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Unintended health consequences of obesity pharmacotherapy.
Figure 1 Unintended health consequences of obesity pharmacotherapy.CC BY · PubMed Central
Figure 2 Nutritional risk and intake monitoring checklist for patients on obesity pharmacotherapy.
Figure 2 Nutritional risk and intake monitoring checklist for patients on obesity pharmacotherapy.CC BY · PubMed Central

Verification

Claims the paper makes

11 Valid · 3 Not valid · 35 Not checked · 24 Own results and interpretations

29 more claims · 1 with their cited sources checked

Create a free account to see all 73 claims and to verify the 43 references still open.

See all claims — free account
  • It may state two separate claims as one. 29
  • Probably not a substantial claim. 12
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 49 references

Cited by

See all 20

Metadata

Authors
Al-Najim, W., Raposo, A., BinMowyna, M. N., & le Roux, C. W.
Affiliations
  • Diabetes Complications Research Centre, School of Medicine, Conway Institute, University College Dublin, D04 V1W8 Dublin, Ireland
  • Universidade Lusófona de Humanidades e Tecnologias (PT)
  • Shaqra University (SA)
Corresponding author
Raposo, António
Venue
Nutrients
Publisher
MDPI AG
Published
2025-06-05
Volume
17
Issue
11
Pages
1934
ISSN
2072-6643 (ISSN-L)
OpenAlex
W4411070513
Cited by
16
References
50
Citations by year
2026: 12 · 2025: 4
FWCI
2.16
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Nursing › Nutrition and Dietetics › Dietetics, Nutrition, and Education
Keywords
obesity pharmacotherapy, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, nutritional complications, caloric restriction, micronutrient deficiency, sarcopenia, lean mass loss, dehydration, ketoacidosis, medication adherence, registered dietitians, dietary assessment, older adults
MeSH terms
Humans, Nutritional Status, Obesity, Treatment Outcome, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes. https://app.cochat.ai/papers/10.3390/nu17111934
The paper
Al-Najim, W., Raposo, A., BinMowyna, M. N., & le Roux, C. W. (2025). Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes. Nutrients. https://doi.org/10.3390/nu17111934

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.